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Amyloid- (A) peptide-binding alcohol dehydrogenase (ABAD), an enzyme present in neuronal mitochondria, exacerbates A-
induced cell stress. The interaction of ABAD with A exacerbates A-induced mitochondrial and neuronal dysfunction. Here, we show
that inhibition of the ABAD-A interaction, using a decoy peptide (DP) in vitro and in vivo, protects against aberrant mitochondrial and
neuronal function and improves spatial learning/memory. Intraperitoneal administration of ABAD-DP [fused to the transduction of
human immunodeficiency virus 1-transactivator (Tat) protein and linked to the mitochondrial targeting sequence (Mito) (TAT-mito-
DP) to transgenic APP mice (Tg mAPP)] blocked formation of ABAD-A complex in mitochondria, increased oxygen consumption and
enzyme activity associated with the mitochondrial respiratory chain, attenuated mitochondrial oxidative stress, and improved spatial
memory. Similar protective effects were observed in Tg mAPP mice overexpressing neuronal ABAD decoy peptide (Tg mAPP/mito-
ABAD). Notably, inhibition of the ABAD-A interaction significantly reduced mitochondrial A accumulation. In parallel, the activity of
mitochondrial A-degrading enzyme PreP (presequence peptidase) was enhanced in Tg mAPP mitochondria expressing the ABAD decoy
peptide. These data indicate that segregating ABAD from A protects mitochondria/neurons from A toxicity; thus, ABAD-A interac-
tion is an important mechanism underlying A-mediated mitochondrial and neuronal perturbation. Inhibitors of ABAD-A interaction
may hold promise as targets for the prevention and treatment of Alzheimer’s disease.
Introduction
Amyloid- peptide (A) has been assigned a central role in the
pathogenesis of Alzheimer’s disease (AD). Mitochondrial dys-
function occurs in early AD. Aberrant mitochondrial function is
known to contribute to alterations in energy metabolism, free
radical generation, and cellular calcium homeostasis, all of which
are relevant to the pathogenesis of AD (Davis et al., 1997; Sheehan
et al., 1997; Humphries and Szweda, 1998; Blass, 2000; Maurer et
al., 2000; Hirai et al., 2001; Bosetti et al., 2002; Floyd and Hensley,
2002; Beal, 2004; Yan and Stern, 2005; Devi et al., 2006; Lin and
Beal, 2006; Shukkur et al., 2006; Yao et al., 2009). Recent studies
have highlighted the significance of the accumulation of A
within mitochondria (Lustbader et al., 2004; Caspersen et al.,
2005; Lin and Beal, 2006; Manczak et al., 2006; Yan et al., 2006;
Du et al., 2008; Hansson Petersen et al., 2008; Yao et al., 2009). A
progressively accumulates in brain mitochondria of Alzheimer’s
patients and transgenic mouse model of AD, exerting a deleteri-
ous effect on mitochondrial function, including energy failure,
altered mitochondrial properties, and elaboration of reactive ox-
ygen species (ROS). However, the key intracellular mechanisms
through which A impairs cellular properties, resulting in neu-
ronal dysfunction and mitochondrial damage, have yet to be
clearly identified.
ABAD (A-binding alcohol dehydrogenase) is a mitochon-
drial enzyme whose unique features include a broad repertoire of
substrates, binding A in the nanomolar range, and potentiating
A-induced cell stress. ABAD is elevated in the cerebral cortex
and hippocampus of AD-affected brain regions and in mouse
models of AD (Yan et al., 1997; He et al., 2002; Lustbader et al.,
2004; Chen and Yan, 2007; Yao et al., 2009). Further, the
ABAD-A complex was found in brain mitochondria of trans-
genic (Tg) mice with neuron-targeted overexpression of mutant
human amyloid precursor protein (Tg mAPP) and Tg mAPP
mice that overexpress ABAD (Tg mAPP/ABAD) (Lustbader et
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al., 2004; Takuma et al., 2005). Overexpression of ABAD exacer-
bates A-mediated mitochondrial and neuronal dysfunction, as
evidenced by reduced enzyme activity associated with complex
IV in the respiratory chain, diminished oxygen consumption,
decreased brain glucose utilization, decreased ATP, and leakage
of mitochondrial-derived ROS. Subsequently, double Tg mAPP/
ABAD mice exhibit an earlier onset of impaired spatial learning/
memory and regional neuropathological changes compared with
single Tg mAPP mice. Previously, we have shown that the inhi-
bition of the interaction of A with ABAD (using the ABAD
decoy peptide) can suppress expression of both peroxiredoxin II
and endophilin I, both of which are elevated in the cerebral cortex
of Tg mAPP, Tg mAPP/ABAD mice and human AD patients (Yao
et al., 2007; Ren et al., 2008). These data led us to hypothesize that
inhibition of the ABAD-A interaction would protect mitochon-
dria and neurons from A-mediated toxicity.
The studies presented herein specifically demonstrate that the
introduction of an ABAD-decoy peptide (ABAD-DP) into Tg
mAPP mice reduces ABAD-A interaction and protects against
A-mediated mitochondrial toxicity. These data provide support
for the premise that ABAD-A interaction is a key factor in po-
tentiating A-induced cytotoxicity, and may also be an effective
target for therapeutic intervention in AD.
Materials and Methods
Mice. Animal studies were approved by the Animal Care and Use Com-
mittee of Columbia University in accordance with the National Institutes
of Health guidelines for animal care. Tg mice overexpress a human form
of mutant APP that encodes hAPP695-, hAPP751-, and hAPP770-
bearing mutations linked to familial AD (V717F, K670M, N671L, J-20
lines) (Mucke et al., 2000). Male mice were used for all the experiments.
Tat-Mito-ABAD-93-116/116-93 peptides synthesis and administration.
Tat-Mito-ABAD-93-116 and Tat-Mito-ABAD-116-93 peptides were
synthesized by the W. M. Keck Facility, Yale University (New Haven,
CT). The sequences of the peptides contain both Tat and Mito (the
amino acids of the mitochondrial targeting) in one-letter code as
follows: YGRKKRRQRRR for cell-membrane transduction domain of
the human immunodeficiency virus 1 (HIV) transactivator protein
(Tat); GIAVASKTYNLKKGQTHTLEDFQR for the specific sequence
of the human ABAD that encompasses the A binding region (residues
93–116 of ABAD). The mouse mitochondrial targeting sequence,
MAAAVRSVKGL, was incorporated between Tat and ABAD-93-116
(DP) and -116-93 [reverse peptide (RP)]. Tat-Mito-ABAD-116-93 was
constructed with a reversed amino acid sequence of ABAD (residues
116 –93) as the corresponding sequence of ABAD residues 93–116. Mito-
ABAD-DP and -RP were labeled with Texas Red (Southern Biotechnol-
ogy Associates) and added to cultured neurons at a concentration of 10
M for 30 min. For examination of mitochondrial localization of Texas
Red-labeled mito-ABAD peptide, neurons were fixed with 4% parafor-
maldehyde, incubated with HSP60 antibody for 30 min, followed by
FITC-conjugated secondary antibody. To examine entry of ABAD pep-
tide into brain, Texas Red-labeled Tat-Mito-ABAD-DP and -RP were
intraperitoneally injected into mice (2.6 mg/kg). At 30 and 120 min after
administration of ABAD peptide, mice were perfused with 4% parafor-
maldehyde and one half of the brains was homogenized immediately and
fluorescently quantified Texas Red at excitation of 550 nm and emission
of 615 nm wavelengths. The other hemisphere was subjected to immu-
nostaining with Hsp60 antibody to examine localization of Texas Red-
labeled ABAD peptide in mitochondria. For the peptide infusion, mice at
the age of 7 months were intraperitoneally injected with Tat-mito-
ABAD-DP, -RP or vehicle daily for 3 months, and then subjected to
experiments.
Generation and characterization of Tg PD-mito-ABAD(92-120) mice.
The human ABAD cDNA containing amino acids 92–120 was subcloned
into the pECFP-Mito vector (Clontech, CA) using BamHI plus AgeI
cloning sites. The transgenic cassettes contain mitochondrial targeting
sequence derived from the precursor of subunit VIII of human cyto-
chrome c oxidase-ABAD(92-120) and green fluorescence protein (GFP,
27 kDa), which is driven by the platelet-derived growth factor 
(PDGF-) chain promoter. Transgenic expression gene cassettes were
generated, isolated as a PvuI fragment, and injected into mouse
B6CBAF1/J oocytes. The oocytes were then implanted into pseudopreg-
nant females, which were subsequently mated with B6CBAF1/J males,
resulting in the generation of three independent founder lines. These
founders were backcrossed into the C57BL/6 background strain for eight
generations. Transgenic mice were genotyped using the following prim-
ers for PCR amplification: 5-GGATCCGCAGGCATCGCGGT-3 and
5-ACCGGTCACATCAAGAACT-3 for ABAD(92-120), 92 bp; and
5-GCTGGTTTAGTGAACCGTCAG-3 and 5-TTGTGGCCGTTTAC-
GTCGCCGT-3 for mitochondrial targeting sequence, ABAD(92-120),
and N-terminal of GFP, 353 bp, respectively. Transgene expression was
verified by immunoblotting and immunostaining with anti-ABAD anti-
body. ABAD(92-120) mice were crossed with mAPP mice to generate
double Tg mAPP/ABAD(92-120) mice along with littermate single Tg
mice [mAPP, ABAD(92-120)], and nontransgenic control mice (non-
Tg). Transgenic mice indicated above were aged to 10 –11 months old for
experiments.
Isolation of brain mitochondria and assays for mitochondrial complex III
and IV activities. Mitochondrial fractions were prepared for determina-
tion of oxygen consumption using a Clark oxygen electrode as previously
described (Caspersen et al., 2005; Du et al., 2008, 2009). Mitochondrial
enzyme activity associated with complexes III and IV were measured
using biochemical methods as previously described (Birch-Machin and
Turnbull, 2001).
Coimmunoprecipitation for detecting mitochondrial A-ABAD com-
plex. Purified mitochondria (500 g) were incubated with lysis buffer for
15 min on ice and then spun for 10 min at 10,000  g. Resulting super-
natants were immunoprecipitated with mouse anti-A IgG (6E10; 8 g/
ml) (Signet Laboratories) at 4°C overnight, then incubated with protein
A/G beads followed by Western blotting with ABAD antibody (1:10,000).
Since the expression levels of cytochrome c oxidase subunit IV (COX IV)
were not significantly changed in Tg mAPP mice compared with that in
non-Tg littermates (data not shown), we used COX IV as mitochondrial
protein loading controls. Equal amounts of mitochondrial protein used
for immunoprecipitation were immunoblotted by mouse anti-COX IV
antibody (1:1000; Invitrogen, Eugene, OR).
Immunoblotting, immunostaining, and measurement of AChE activity.
Cerebral cortical homogenates from Tg mice were subjected to immuno-
blotting using monoclonal anti-ABAD (1:8000), 6E10 (1:1000; Signet), or
mouse anti-COX IV IgG (1:4000; Sigma). Binding sites of primary anti-
body were visualized with affinity-purified peroxidase-conjugated goat
anti-rabbit IgG or goat anti-mouse IgG (1:5000; Sigma) followed by the
addition of ECL substrate (GE Healthcare), and completed with chemilu-
minescence. Relative intensity of gel bands was quantified using NIH
ImageJ software. Immunohistochemistry was performed on mice brain
sections. After 6 min of perfusion with saline, brains were fixed in para-
formaldehyde (4%) for 26 h. Serial vibratome sectioning (20 m) was
completed and immunocytochemical analyses were performed using
rabbit anti-ABAD IgG (10 g/ml). For on-slide immunohistochemistry,
sites of primary antibody binding were visualized using peroxidase-
conjugated goat anti-rabbit IgG and 3-amino-9-ethyl carbazole (Sigma)
as the detection system. AChE activity was determined histochemically
using a commercial kit (Invitrogen). The quantification of images was
performed using computer software (Universal Image) to determine the
percentage area occupied. To ensure objective assessments and reliability
of results, brain sections from mice in any given experiment were blindly
coded and processed in parallel. Codes were revealed after the analysis
was complete.
Assessment of ROS in vivo. The production of superoxide was mea-
sured by monitoring hydroethidine (HEt) (Invitrogen) levels in neurons
of mouse brains, as previously described by Murakami et al. (1998).
Briefly, 5 mM HEt stock solution was diluted to 1 mg/ml in PBS. Tg mice
were intravenously injected with diluted HEt solution (6.7 g/kg). Thirty
minutes later, animals were perfused with 4% paraformaldehyde, imme-
diately followed by cryostat brain sectioning and analysis using confocal
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microscopy. Brain sections were processed for immunostaining with
anti-Hsp60 (mitochondrial marker) to determine signal localization in
mitochondria. Half of these mouse brain tissues were homogenized by 10
strokes in a glass Teflon homogenizer in 1 ml of the brain homogenizing
buffer; this was immediately followed by fluorescent quantification in a
96-well microplate with an excitation of 415 nm and emission of 510 nm
using a fluorescent microplate reader (Molecular Devices).
4-Hydroxy-2-nonenal (HNE-4) was measured by immunochemistry
assay. Brain sections were stained with mouse anti-HNE-4 antibody and
the percentage of area occupied by HNE-4 staining in hippocampus was
quantified using Universal Image Computer Software.
Behavioral evaluation. Behavioral studies were performed to assess
spatial learning and memory in the radial arm water maze as previously
described (Arancio et al., 2004; Lustbader et al., 2004; Du et al., 2008).
Investigators were blinded to mouse genotypes until completion of be-
havioral testing. Mice were allowed 60 s to find the hidden platform and
errors were counted. Mice that failed to find the platform within 60 s were
guided to the hidden platform and stayed on the platform for 10 s.
Retention memory was assessed 30 min after the initial water maze
experiment.
A degradation assay for determination of PreP activity. Purified mito-
chondrial matrix PreP (presequence peptidase) protein from Tg mice
was incubated with biotin-A1– 42 in a degradation buffer containing 20
mM HEPES-KOH, pH 8.0, and 10 mM MgCl2 at 37°C for 3 h. The mix-
tures were then centrifuged at 4°C and 10,000  g for 10 min, incubated with
avidin agarose to pull down A, and then subjected to immunoblotting.
Biotinylation of A1– 42 was revealed by extra-avidin-conjugated anti-
body and ECL. Immunoinactivation was performed by preincubating
mitochondrial fractions with 6 g of antibodies raised against hPreP
(provided by Dr. Elzbieta Glasser, Stockholm University, Stockholm,
Sweden) at 4°C for 30 min before the addition of biotin-labeled A1-42.
Statistical analyses were performed using StatView software. ANOVA
was used for repeated measures followed by Fisher’s protected least sig-
nificant difference for post hoc comparisons. Results are expressed as
mean  SEM.
Results
Administration of mito-ABAD-DP prevents ABAD-A
complex formation and preserves mitochondrial function in
Tg mAPP mice
In view of the potentially key role of ABAD binding to A in
A-induced mitochondrial dysfunction, we sought to determine
the effect of antagonizing ABAD/A interaction on mitochon-
drial and neuronal function in an A-rich environment, as pro-
vided by a transgenic AD-type mouse model. Amino residues
94 –116 of ABAD are considered as major binding sites in ABAD
mediating binding to A (Lustbader et al., 2004; Takuma et al.,
2005). Thus, we made an ABAD decoy peptide, which we had
successfully used previously to block interaction of ABAD with
A (Lustbader et al., 2004). The decoy peptide alone is not toxic
to the cells (Lustbader et al., 2004). Specifically, to introduce the
ABAD peptide inside cells, we used an 11 aa transduction domain
of HIV Tat fused with an ABAD(93-116) peptide (ABAD-DP) or
its reverse version (ABAD-RP) to allow rapid transduction into
intact tissue. To concentrate ABAD-DP within mitochondria, the
site of ABAD-A complex formation, a mitochondrial targeting
sequence derived from mouse ABAD was also added to Tat-
ABAD-DP and -RP. Supplemental Figure S1, A–G (available at
www.jneurosci.org as supplemental material), shows the mito-
chondrial localization of ABAD peptide in brain and cultured
neurons.
First, we performed immunoprecipitation followed by immu-
noblotting to demonstrate an ABAD-A complex. Immunopre-
cipitation of cortical mitochondria with anti-A IgG (6E10),
followed by immunoblotting with anti-ABAD IgG that recog-
nizes intact ABAD and the decoy peptide, revealed a strong im-
munoreactive band corresponding to Mr 27 kDa of the
endogenous ABAD protein (the latter ABAD was immunopre-
cipitated in complex with A by the anti-A antibody), in
vehicle- and mito-ABAD-RP-treated Tg mAPP mice (Fig. 1A,
lanes 3–5 and 6 –7, respectively), In contrast, two immunoreac-
tive bands (Mr 27 and 5 kDa) were detected in cortical mito-
chondria from mito-ABAD-DP-treated Tg mAPP mice (Fig. 1A,
lanes 8 –10; the 5 kDa band corresponds to immunoreactive
ABAD-DP immunoprecipitated in complex with A). The inten-
sity of the immunoreactive band corresponding to Mr 27 kDa
was significantly decreased (due to decreased amounts of intact
ABAD in complex with A), whereas a strong immunoreactive
band, Mr 5 kDa (corresponding to increased amounts of A
complexed with the ABAD-DP), was observed in cortical mito-
chondria from Tg mAPP mice treated with mito-ABAD-DP for 3
months (from 7 to 10 months of age) (Fig. 1A, lanes 8 –10). In
contrast, the 5 kDa immunoreactive band was undetectable in
mitochondrial extracts from vehicle-treated or mito-ABAD-RP-
treated Tg mAPP mice. Mito-ABAD-RP treatment did not dis-
rupt the formation of the ABAD (full-length)-A complex (Fig.
1A, lanes 6 –7, B). Densitometry of combined immunoreactive
bands for ABAD/AB and ABAD-DP/A (5 kDa) is shown in
Figure 1, B and C, respectively. These results indicate that mito-
ABAD-DP competitively binds mitochondrial A, diminishing
ABAD/A complex formation in mitochondria from Tg mAPP
mice.
Next, we examined whether inhibition of the ABAD-A in-
teraction by administration of mito-ABAD-DP preserved mito-
chondrial function. Mitochondrial function was evaluated by
measuring the respiratory chain rate, activity of mitochondrial
enzymes associated with the respiratory chain, and generation of
reactive oxygen species. As shown in Figure 2, A and B, mito-
chondria from vehicle-treated Tg mAPP mice exhibited signifi-
cantly reduced oxygen consumption, and reduced activity of
mitochondrial enzymes associated with complexes III and IV. We
did not find significant alterations in the expression levels of COX
IV in Tg mAPP mice compared with non-Tg mice based on im-
Figure 1. Effect of systemic administration of mito-ABAD peptide on the formation of ABAD-A
complex in Tg mAPP mice. A, Brain mitochondria isolated from vehicle-treated non-Tg or Tg mAPP
mice, and Tg mAPP mice treated with mito-ABAD-DP or mito-ABAD-RP were subjected to immuno-
precipitation with 6E10 antibody followed by immunoblotting with anti-ABAD IgG. Top, Two immu-
noreactivebands(Mr27and5kDa)weredetected.Bottom,ImmunoblottingforCOXIVshowing
anequalamountofmitochondrialproteinusedfortheexperiments. B, C,Quantificationof intensityof
the immunoreactive bands corresponding to Mr 27 (B) and5 kDa (C). n3– 6 mice per group.
*p  0.01 compared with vehicle- or mito-ABAD-RP-treated mAPP mice.
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munoblotting for COX IV (data not shown), which differ from
the observation in 3xTg APP mice (Yao et al., 2009). The discrep-
ancy of changes in COX IV expression between Tg mAPP mice
and other AD mice (Yao et al., 2009, 2010) could be due to the
mouse model, gender, and COX IV antibody to specific subunit
used in experiments. Tg mAPP mice treated with mito-
ABAD-DP for 3 months starting at 7 months of age, in turn,
exhibited preservation of oxygen consumption and complex
III/IV activity compared with Tg mAPP treated with vehicle or
mito-ABAD-RP (Fig. 2A,B).
Because mitochondria are the major source of ROS genera-
tion and it is known that overexpression of ABAD in Tg mAPP
mice enhances ROS generation (Lustbader et al., 2004), it was
logical to assess the effect of blocking ABAD-A interaction on
oxidative stress. As shown in Figure 2C, levels of HNE-4, a marker
of oxidized products including lipid and protein, were signifi-
cantly increased in the hippocampus of vehicle- or mito-ABAD-
RP-treated Tg mAPP mice, compared with the vehicle-treated
non-Tg littermates. In contrast, mito-ABAD-DP-treated Tg
mAPP mice showed greatly reduced levels of HNE-4 (70%)
compared with vehicle-treated Tg mAPP mice. These data indi-
cate that administration of mito-ABAD-DP inhibits interaction
of ABAD with A within mitochondria and consequently pro-
tects mitochondria from A toxicity.
Administration of Mito-ABAD-DP improves spatial learning/
memory in Tg mAPP mice
Next, we evaluated whether the protective effect of mito-
ABAD-DP on compromised mitochondrial function in mAPP
mice might impact behavioral outcomes. Tg mAPP mice (7
months of age) were treated daily with mito-ABAD-DP for 3
months and then evaluated for radial arm water-maze perfor-
mance. As expected, vehicle-treated Tg mAPP mice displayed a
poorer performance than non-Tg littermates after the second
training trial in the acquisition series (A1–A4) and in the fifth
retention trial (R, vehicle-treated Tg mAPP mice: 5– 6.5 errors;
vehicle-treated-non-Tg: 1–2.5 errors) (Fig. 2D). Administration
of mito-ABAD-DP largely reduced the gap between vehicle-
treated non-Tg mice (mito-ABAD-DP-treated Tg mAPP: 2.5
errors) during the acquisition and retention trials. The control
peptide (mito-ABAD-RP) did not rescue memory impairment.
These studies demonstrate that blockade of ABAD-A interac-
tion improved learning and memory in Tg mAPP mice.
Effect of transgene ABAD(92-120) on ABAD/A interaction
and mitochondrial function in Tg mAPP/mito-ABAD mice
The results generated from systemic administration of ABAD
peptide (DP) indicate the protective effects of ABAD-DP on mi-
tochondrial and neuronal function in Tg mAPP mice. To further
confirm the effects of blocking the ABAD-A interaction and to
dissect the role of neuronal ABAD in A-mediated mitochon-
drial perturbation, we generated transgenic mice with neuronal
and mitochondria-targeted expression of ABAD(92-120) that
encompasses the binding region of ABAD to A under control of
the PDGF- chain promoter, termed Tg mito-ABAD (supple-
mental Fig. S2, available at www.jneurosci.org as supplemental
material). To assess the effect of transgene [ABAD(92-120)] in an
A-rich environment, Tg mito-ABAD mice were crossed with
animals expressing a mutant form of human APP driven by
PDGF- chain promoter (Tg mAPP), which are known to have
high levels of A in the cerebral cortex and mitochondria (Aran-
cio et al., 2004; Lustbader et al., 2004; Caspersen et al., 2005; Du et
al., 2008), mitochondrial and neuronal dysfunction, and impair-
ments in learning/memory (Arancio et al., 2004; Lustbader et al.,
2004; Takuma et al., 2005). Double transgenic mice (Tg mAPP/
mito-ABAD) display A and ABAD(92-120) in mitochondria,
which allowed us to test whether the inhibition complex forma-
tion between full-length ABAD and A in mitochondria would
occur in the presence of ABAD(92-120) in Tg mAPP/mito-
ABAD mice. First, we performed immunoprecipitation of brain
mitochondria with anti-A (6E10) followed by immunoblotting
with anti-ABAD IgG. The results showed strong immunoreactive
bands corresponding to Mr 27 kDa, a complex of full-length
ABAD with A, in Tg mAPP mice (Fig. 3A, lanes 1–3), and Mr 5
kDa, a complex of ABAD(92-120) with A, in the double Tg
mAPP/ABAD(92-120) mice (Fig. 3A, lanes 4 – 6). Complex for-
mation between full-length ABAD and A, demonstrated as a Mr
27 kDa ABAD-immunoreactive band was significantly reduced
in brain mitochondria of Tg mAPP/mito-ABAD mice compared
with the single Tg mAPP mice (Fig. 3A,B). These data indicate
that ABAD(92-120) interacts with mitochondrial A, which in
turn prevented formation of a complex between full-length
ABAD and A. This observation was consistent with the results in
which we systematically administered mito-ABAD-DP to Tg
mAPP mice. We propose that the presence of ABAD-DP or
ABAD(92-120) in mitochondria prevented ABAD-A complex
formation, thereby preventing mitochondrial perturbation.
To further assess this concept, we evaluated mitochondrial
function, including oxygen consumption, activity of the respira-
tory chain complexes, and generation of ROS. Consistent with
our previous studies (Caspersen et al., 2005; Du et al., 2008,
2009), Tg mAPP mice at the age of 10 –12 months displayed
abnormal mitochondrial function as evidenced by the reduction
in respiratory chain rate (Fig. 3C), and enzymatic activity of com-
plex III–IV (supplemental Fig. S3A,B, available at www.
jneurosci.org as supplemental material). However, mitochondria
purified from double Tg mAPP/mito-ABAD animals demon-
Figure 2. Effect of systemic administration of mito-ABAD peptide on mitochondrial function
and spatial memory. A, B, Effect on mitochondrial function. The respiratory control rate (RCR)
(A), and enzyme activities associated with complexes III and IV (B) were determined in the brain
mitochondria isolated from the indicated Tg mice. C, Quantification of the area occupied by
HNE-4 staining in hippocampus of the indicated Tg mice. n  3– 8 mice per group. D, Spatial
learning and memory were tested using a radial arm water maze in Tg mAPP mice treated with
vehicle, mito-ABAD-DP (DP), or mito-ABAD-RP (RP), and non-Tg mice or Tg mAPP mice treated
with vehicle (n  7–11 mice per group). A1–A4 denote the acquisition trials, and R denotes the
retention trial. *p  0.01 compared with vehicle- or mito-ABAD-RP-treated Tg mAPP mice.
#p  0.05 compared with vehicle-treated non-Tg mice.
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strated virtually complete preservation of oxygen consumption,
as well as complex III and IV enzyme activity. Since overexpres-
sion of ABAD in Tg mAPP mice enhanced ROS generation (Yan
et al., 1999; Lustbader et al., 2004), we examined whether blocking
ABAD/A interaction in Tg mAPP/mito-ABAD mice attenuated
ROS production. Specifically, we studied mitochondria-derived
ROS production using HEt, a fluorescent dye that is oxidized to
ethidium selectively by superoxide (Murakami et al., 1998). In-
travenous HEt injection was administered to mice followed by
quantification of Het fluorescence intensity in the brain. Fluores-
cence intensity was significantly greater in brain homogenates of
Tg mAPP mice than other groups of mice. However, there was an
50% reduction of HEt fluorescent intensity in the brain of Tg
mAPP/mito-ABAD mice compared with Tg mAPP mice (Fig.
3D). Quantification of the HEt-stained area in brain sections
showed decreased superoxide production by 40% and 70%, re-
spectively, in the cerebral cortex and the hippocampus of Tg
mAPP/mito-ABAD mice, compared with those in the single Tg
mAPP mice (Fig. 3E,F). The fluorescent signals were distributed,
at least in part, in mitochondria, as shown by colocalization of
Hsp60 (a mitochondrial marker) with HEt staining (supplemen-
tal Fig. S3C–E, available at www.jneurosci.org as supplemental
material), indicating mitochondrial production of superoxide.
These data are consistent with the hypothesis that blockade of the
interaction of intact ABAD with A decreases generation of mi-
tochondrial oxygen-free radicals.
Effect of transgene ABAD(92-120) on neuropathology and
spatial learning/ memory in Tg mAPP/mito-ABAD mice
In view of the known exaggerated neuronal dysfunction and ac-
celerated decline in spatial learning/memory induced by the
ABAD-A interaction (Lustbader et al., 2004; Chaney et al.,
2005), we proposed that inhibition of this interaction would have
a beneficial/protective effect on neuronal function. The density of
cholinergic fibers and synapses is diminished in AD-like pathol-
ogy and in accelerated AD-type mouse models (Geula, 1998;
Mucke et al., 2000; Arancio et al., 2004;
Lustbader et al., 2004; Chaney et al., 2005;
Yan and Stern, 2005; Fang et al., 2009).
Thus, we measured AChE enzyme activity
and semiquantitatively analyzed the den-
sity of AChE activity-positive neurites
(which predominantly labels cholinergic
neurites) in Tg mice using a standard his-
tochemical method. AChE-positive neu-
rites were shown as positively staining
neurites in the subiculum. Consistent with
our previous observations (Arancio et al.,
2004; Yan and Stern, 2005; Fang et al., 2009),
at 10–12 months of age, the area occupied
by AChE-positive neurites in the subiculum
was decreased in Tg mAPP mice ( p  0.01),
compared with non-Tg littermates and Tg
mito-ABAD mice (Fig. 4A). In contrast,
double Tg mito-mAPP/mito-ABAD mice
showed significantly less reduction in
AChE-positive neurites (Fig. 4A). Repre-
sentative images of AChE histochemically
stained subiculum sections from each geno-
type are shown in supplemental Fig. S4,
available at www.jneurosci.org as supple-
mental material. Consistent with histo-
chemical studies, AChE activity was also
significantly reduced in the subiculum region of Tg mAPP mice (Fig.
4B). Notably, non-Tg and Tg mito-ABAD mice do not display such
abnormalities. Further, introduction of ABAD(92-120) attenuated
this A-mediated regional neuropathologic change, suggesting the
critical role of mitochondrial A interaction with ABAD.
To determine whether neuropathologic changes would be re-
flected in neuronal dysfunction, we performed behavioral analy-
sis using the radial arm water maze to assess spatial learning/
memory in these Tg mice. At 10 –12 months of age, non-Tg and
Tg mito-ABAD mice displayed normal spatial learning as shown
by an average of 2–2.5 errors, whereas Tg mAPP mice averaged
5– 6 errors by trials 3–5, indicating impaired spatial memory
for platform location between trials. However, double Tg mAPP/
mito-ABAD mice exhibited 3 errors by trial 3–5 (Fig. 4C). No-
tably, Tg mito-ABAD and non-Tg littermates displayed identical
performance in this behavioral task, suggesting that overexpres-
sion of ABAD(92-120) does not affect spatial memory. These
data indicate that blockade of ABAD-A interaction improves
neuronal function, and learning/memory in mAPP mice.
Antagonizing ABAD peptide reduces accumulation of
mitochondrial A and increases PreP activity in Tg mAPP
mice
Since systemic administration of mito-ABAD-DP and overex-
pression of the ABAD(92-120) transgene in Tg mAPP mice sig-
nificantly reduced ABAD-A complex formation, we sought to
determine the effect of this ABAD-derived peptide on mitochon-
drial A accumulation. We encountered an unexpected finding
that mitochondrial A levels (including A40 and -42) were sig-
nificantly reduced in Tg mAPP mice treated with mito-
ABAD-DP by 2- to 4-fold in the cortical mitochondrial fractions,
but not in Tg mAPP mice treated with reversed control peptide,
compared with single Tg mAPP mice (Fig. 5A,B). Similarly, Tg
mAPP mice overexpressing ABAD(92-120) had significantly de-
creased levels of A40 and A42 by 3- to 4-fold in the cortical
mitochondrial fractions (Fig. 5C,D). These results indicate that
Figure 3. Expression of ABAD(92-120) reduces ABAD-A complex formation, restores mitochondrial function, and attenuates
generation of ROS. A, Immunoprecipitation of cortical mitochondria of the indicated Tg mice with 6E10 followed by immunoblot-
ting with anti-ABAD showed two immunoreactive bands, Mr 27 (ABAD/A complex) and 5 kDa [ABAD(92-120)/A com-
plex)]. Bottom shows immunoblotting of cortical mitochondrial fractions with -COX IV. B, C, Quantification of intensity of
immunoreactive bands corresponding to Mr 27 and 5 kDa (B) and oxygen consumption (C, respiratory control ratio) in cortical
mitochondria from the indicated Tg mice. D, Fluorescence intensity of HEt (indicator of ROS) in brain homogenates. E, F, Quanti-
fication of area occupied by HEt staining in the cerebral cortex (E) and hippocampus (F ) of the indicated Tg mice. *p  0.01 vs Tg
mAPP mice. n  3– 6 mice per group.
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blockade of the ABAD-A interaction in Tg mAPP mice dimin-
ished A accumulation within mitochondria and led us to next
determine the fate of mitochondrial A in Tg mAPP mice over-
expressing ABAD(92-120).
The presequence peptidase, PreP, is a recently identified novel
mitochondrial peptidase responsible for degrading presequences
and other short unstructured peptides (70 aa) in mitochondria.
The human PreP homolog (hPreP) is localized in the mitochon-
drial matrix and is a protease capable of degrading A (Falkevall
et al., 2006). We speculated that PreP might play a role in degrad-
ing mitochondrial A in the in vivo environment, and may there-
fore be responsible for the reduction of mitochondrial A levels
seen in Tg mAPP mice expressing ABAD(92-120). Therefore, we
performed a series of experiments to determine whether PreP
plays a role in lowering mitochondrial A in Tg mAPP/mito-
ABAD mice. First, we examined PreP activity in Tg mAPP mice
using a degradation assay. Brain mitochondria containing PreP
isolated from Tg mice were incubated with a biotin-labeled A42
peptide followed by pull-down of the biotin-labeled A42 with
avidin-conjugated agarose. Samples were then subjected to West-
ern blot analysis to determine the capacity of mitochondrial PreP
to degrade exogenous biotin-labeled A42. PreP from non-Tg brain
mitochondria revealed complete degradation of A as demon-
strated by undetectable or very weak A-immunoreactive bands
(Fig. 5E, lanes 4–7). In contrast, PreP from
Tg mAPP mitochondria showed strong im-
munoreactive A bands (Fig. 5E, lanes
8–11), suggesting that PreP degrading activ-
ity was significantly reduced in Tg mAPP
mitochondria. Notably, PreP from Tg
mAPP/mito-ABAD mitochondria was able
to degrade A by 80% compared with
mAPP mitochondria (Fig. 5E, lanes 12–15,
F), suggesting increased PreP activity in Tg
mAPP/mito-ABAD mice. Quantification of
the combined density of all immunoreactive
bands is shown in Figure 5F. To determine
the extent of PreP-dependent degradation
of A, we performed immunoinactivation
assays with a specific antibody to PreP. In
the absence of PreP antibody, we found that
recombinant PreP protein (Fig. 5E, lane 2)
or mitochondrial matrix PreP protein (Fig.
5E, lanes 4–7, F) almost completely de-
graded A compared with samples without
mitochondrial PreP protein (Fig. 5E, lane
1). Neutralization of the recombinant PreP
protein or the mitochondrial matrix PreP
protein with PreP antibody revealed an al-
most complete inhibition of the biotin-
labeled A42 degradation (Fig. 5E, lanes 3,
16–19, F). This result is demonstrated by
A-immunoreactive bands, indicating the
specific effect of PreP on A degradation.
Discussion
The present study provides support for a
pathologic role of the ABAD-A interaction
in promoting mitochondrial and neuronal
dysfunction in an A-rich environment, as shown in a mouse model
of AD. We have demonstrated substantial evidence of the protective
effect of blocking the ABAD-A interaction using a combination of
genetic and biochemical approaches applied to this mouse model.
Initially, using the yeast two-hybrid system, and, subsequently,
by ligand binding assays with purified polypeptides and crystal
structure analysis, our group identified an ABAD polypeptide
capable of binding A (Yan et al., 1997; Lustbader et al., 2004).
Next, we identified an ABAD-A complex in vivo in cortical mi-
Figure 4. Neuropathology and behavior in mAPP/mito-ABAD mice. A, AChE-positive neu-
rites were visualized histochemically in the subiculum (Sb) of the indicated Tg mice. B, AChE
activity in the subiculum of the indicated Tg mice. *p  0.01 vs other groups of mice. C,
Behavioral studies in Tg mice. Spatial learning and memory was tested in the radial arm water
maze in the indicated Tg mice. A1–A4 denote the acquisition trials, and R denotes the retention
trial. *p  0.01 Tg mAPP mice vs other groups of mice. n  4 – 8 mice per group.
Figure 5. Effect of ABAD antagonizing peptide on accumulation of mitochondrial A in Tg mAPP mice. A, B, ELISA for mea-
surement of mitochondrial A40 (A) and -42 (B) levels in Tg mAPP mice treated with Mito-ABAD-DP or -RP at age of 10 –11
months. *p  0.01 vs vehicle- or Mito-ABAD-RP-treated Tg mAPP mice. C, D, ELISA for A40 (C) and A42 (D) in the cortical
mitochondria from the indicated Tg mice at 10 –11 months old. *p  0.01 vs Tg mAPP mice. E, PreP activity for degradation of
biotin-A. F, Quantification of density of all A-immunoreactive bands incubated with mitochondrial fractions from non-Tg
littermates (lanes 4 –7), Tg mAPP mice (lanes 8 –11), double Tg mAPP/mito-ABAD (lanes 12–15), and Tg mAPP/mito-ABAD plus
anti-PreP antibody mice (lanes 16 –19) using NIH ImageJ software. *p  0.01 vs other groups of mice. n  5–10 mice per group.
2318 • J. Neurosci., February 9, 2011 • 31(6):2313–2320 Yao et al. • ABAD-A Inhibition Protects Mitochondria in AD
tochondria from AD brain and transgenic AD mice (Lustbader et
al., 2004). Importantly, the ABAD-A interaction exacerbates
mitochondrial and neuronal dysfunction in AD mice and in A-
induced neuronal injury (Yan et al., 1999; Lustbader et al., 2004;
Takuma et al., 2005; Yan and Stern, 2005), indicating that the
interaction of ABAD with A is critical for facilitating A-
induced mitochondrial and neuronal stress. These studies raised
the question as to whether the blockade of the ABAD-A inter-
action might attenuate these deleterious effects observed in
APP/A mice or in A-perturbed neurons.
To block ABAD-A interaction, we used an ABAD decoy pep-
tide to compete with and neutralize the binding of A to endog-
enous full-length ABAD. The choice of peptide was guided by
structural studies demonstrating that residues (94–114) of ABAD
comprise the site of A binding, and a peptide encompassing this
region (residues 92-120) of human ABAD (ABAD-DP) inhibited
binding of ABAD to A based on surface plasmon resonance
(Lustbader et al., 2004). Further in vitro experiments revealed
that the addition of cell-permeable ABAD-DP, the latter with the
cell-membrane transduction domain of HIV Tat protein, to cul-
tured cortical neurons largely prevented A-induced cyto-
chrome c release, ROS production, and apoptosis (Lustbader et
al., 2004).
In the present study, we demonstrate the protective effects of
inhibition of ABAD-A binding on mitochondrial properties
and cognitive function in an in vivo setting. First, using a recom-
binant molecular technique, we constructed a biologically active
ABAD(93-116) peptide fused to the HIV Tat transduction pro-
tein domain and a mitochondrial targeting sequence. The protein
transduction domain embedded in the HIV Tat protein (47–57)
has been successfully used to study intracellular mechanisms
based on high efficiency (90%) delivery of peptides/polypep-
tides both in vitro and in vivo (Lissy et al., 2000; Aarts et al., 2002;
Cao et al., 2002; Wadia and Dowdy, 2002). It has been shown that
Tat-linked proteins can penetrate the blood– brain barrier; thus
Tat-mediated delivery of proteins/peptides holds potential for
future therapeutic applications. The presence of the membrane
transduction and mitochondrial targeting domains results in ef-
fective penetration and concentration of polypeptides into mito-
chondria in an intact tissue. As we observed, Tat-ABAD peptide
was efficiently transduced to neurons and localized to mitochon-
dria in vitro and in vivo.
Indeed, we have successfully used this decoy peptide before to
demonstrate in vivo effects. Specifically, from a proteomic study
of proteins with elevated expression in Tg mAPP/ABAD mice, we
identified two proteins, peroxiredoxin II and endophilin I,
present at higher levels in the cerebral cortex of Tg mAPP, Tg
mAPP/ABAD mice and human AD patients (Yao et al., 2007; Ren
et al., 2008). These two proteins typify the complex changes in
protein expression in AD brain, as the expression of peroxire-
doxin II and endophilin I has the potential to either promote or
inhibit neuronal survival, respectively (Yao et al., 2007; Ren et al.,
2008). Using the expression of these two proteins as a biological
marker, we showed that the Tat-Mito-ABAD-DP decoy peptide,
when injected intraperitoneally into Tg mAPP mice (using the same
protocol as in the current study) had the ability to diminish expres-
sion of these two proteins to normal levels while the reverse peptide
was inactive in this regard (Yao et al., 2007; Ren et al., 2008).
In this study, we have gone further and directly observed that
introduction of ABAD decoy peptide in vivo dissociates ABAD
from A with resultant restoration of ABAD function and PreP
activity. In parallel, treatment with the ABAD decoy peptide de-
creased formation of the ABAD-A complex, restored mito-
chondrial respiratory function and enzyme activity, attenuated
mitochondrial ROS production/accumulation, increased activity
of A degrading enzyme, and, presumably, thereby improved
learning and memory. Similar results were observed in Tg mAPP
mice overexpressing neuronal ABAD decoy peptide. Together,
these observations confirm the protective effects of ABAD decoy
peptide.
Intriguingly, mitochondrial A levels were significantly lower
in Tg mAPP mice treated with the ABAD decoy peptide or in
mice expressing this peptide versus vehicle-treated mAPP mice.
Furthermore, PreP proteolytic activity was decreased in A-rich
mitochondria, but was significantly enhanced in the presence of
the ABAD decoy peptide. It has been demonstrated that human
PreP is the sole A-degrading protease responsible for degrada-
tion and clearance of A in mitochondria recognized to date.
Impaired PreP activity would therefore promote accumulation of
A, ultimately causing aberrant mitochondrial and neuronal
function (Falkevall et al., 2006). In situ immunoinactivation
studies using anti-PreP antibody eliminated degradation of A,
proving that PreP is necessary for the clearance of A in mito-
chondria. Thus, decreased PreP activity may be an important
mechanism underlying A accumulation in mitochondria in
mAPP mice.
Given that proteolytic activity of PreP under oxidizing condi-
tions was associated with A accumulation (Falkevall et al.,
2006), we predicted that diminished PreP activity, observed in
the presence of ABAD-A complex (i.e., in Tg mAPP mice),
would occur in tandem with higher levels of mitochondrial ROS.
Consistent with this concept, in the presence of ABAD-DP
(which dissociated the complex between full-length ABAD and
A), levels of ROS were reduced and PreP demonstrated the
ability to degrade A. These data are also consistent with the
changes in mitochondrial A levels in Tg mice, which were ele-
vated in Tg mAPP mice and reduced by administration of
mito-ABAD-DP.
Together, these findings provide substantial evidence of the
protective effect of inhibition of ABAD-A interaction on mito-
chondrial, neuronal, and cognitive function in an AD mouse
model. Most importantly, we demonstrated that blockade of
ABAD-A interaction reduces mitochondrial A accumulation,
leading to improvement in mitochondrial function, attenuation
of mitochondrial ROS production, and increased PreP activity.
Elevated levels of oxidative stress in mitochondria due to a direct
effect of A or ABAD-A interaction may be responsible for
decreased PreP activity, which in turn leads to further accumula-
tion of A, and exacerbates mitochondrial and neuronal dys-
function, all of which contribute to the picture of AD
pathogenesis. These results provide the first mechanistic insight
into A perturbation of mitochondrial function in AD. One or
more agents that block ABAD-A interaction may therefore be
potential therapeutic approaches for preventing and/or halting
AD progression.
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